Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 ...

In an oral presentation at ASGCT, Editas reported that a single dose of EDIT-401 achieved ≥90 percent mean LDL-C reduction across all dose groups in non-human primates (NHPs). ≥90 percent mean LDL-C ...
Nasdaq

Editas Medicine Progresses Towards Two In Vivo Editing Development Candidates by Mid-2025 and Expands Research Pipeline

Editas Medicine reports advancements in in vivo gene editing, financial results, and plans for upcoming development candidates by mid-2025. Editas Medicine, Inc. announced its progress in developing ...
Seeking Alpha

Editas Medicine, Inc. (EDIT) Lead In Vivo Development Candidate Webinar Transcript

Good morning, everyone, and thank you for joining Editas Medicine webinar to unveil our lead development candidate, EDIT-401. This webinar is being recorded and can be accessed in the future through ...